Gradolatto A, Basly JP, Berges R, Teyssier C, Chagnon MC, Siess MH, et al
The main evidence involves cells, rats and mice
In the 1 mg trial arm, liver fat fell 51% among participants with fatty liver, visceral fat fell 16%, triglycerides declined, and ketones rose as the liver used more fat. Modeled metabolic-health protocols place heavier, metabolically average profiles near 1 mg weekly
Rhodamined TLR2 Pep-Orid-Liposome Efficiently Accumulated and Retained In Vivo To explore the bio-distribution of TLR2 pep-conjugated drug, we prepared rhodamine-labeled orid-liposome and TLR2 pep-orid-liposome
Yet the evidence is heterogenous: most trials are single-arm, lack placebo controls and use disparate endocrine endpoints, making efficacy comparisons precarious [195, 196]
Vanderbilt University